Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Optomed Plc - Managers' transactions - Tauriainen

Optomed Plc Managers' transactions  6 August 2021 at 13.15, Helsinki Optomed Plc - Managers' transactions - Tauriainen ____________________________________________ Person subject to the notification requirement Name: Tauriainen, Reijo Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20210806081326_7 ____________________________________________ Transaction date: 2021-08-06 Venue not applicable Instrument type: SHARE ISIN:

Optomed Plc - Managers' transactions - Tenstam

Optomed Plc Managers' transactions  6 August 2021 at 13.15, Helsinki Optomed Plc - Managers' transactions - Tenstam ____________________________________________ Person subject to the notification requirement Name: Tenstam, Anna Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20210806081326_8 ____________________________________________ Transaction date: 2021-08-06 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Optomed Plc - Managers' transactions - Mäkinen

Optomed Plc Managers' transactions  6 August 2021 at 13.15, Helsinki Optomed Plc - Managers' transactions - Mäkinen ____________________________________________ Person subject to the notification requirement Name: Mäkinen, Seppo Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20210806081326_6 ____________________________________________ Transaction date: 2021-08-06 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Vestas secures 126 MW EnVentus order in Finland

News release from Vestas Northern & Central EuropeHamburg, 6 August 2021 Vestas has received a 126 MW order from Taaleri Energia for the Isoneva project in Finland, adding to the more than 1.8 GW in firm orders already received in Finland for the EnVentus platform. The order includes supply, installation 21 V162-6.0 MW turbines from Vestas’ EnVentus platform. This order follows the 126 MW order received from Taaleri Energia for the Murtotuuli project in the second quarter of 2021. Vestas will provide service for the Isoneva project through a long-term Active Output Management

Lehto Group Plc will publish the Half Year Financial Report for 2021 on 12 August 2021

Invitation for investors and mediaLehto Group Plc6 August 2021 at 13.00 (EET)Lehto Group Plc will publish the Half Year Financial Report for 2021 on 12 August 2021 at 7.30 a.m. (EET) The report in Finnish and English will be available on Lehto’s website. Conference online Lehto Group will hold a conference on the Half Year Financial Report for the media, analysts and investors on Thursday 12 August 2021 at 9:30 a.m. (EET). Due to the prevailing corona situation, the event will only be held online. The conference can also be followed as a live webcast on Lehto’s website at lehto.fi/

Change in Optomed’s holding of treasury shares

Optomed Plc         Stock Exchange Release    6 August 2021 at 13, Helsinki Change in Optomed’s holding of treasury shares Optomed has conveyed 2,461 treasury shares to the members of the Board of Directors as a part of the Board members' annual remuneration in accordance with the decision of the Annual General Meeting 2021. The amount of shares is based on the monthly remuneration decided by the Annual General Meeting and Optomed's value weighted average share price on 4 August 2021. Furthermore, a total of 143,250 of shares have been subscribed for under the Company’s stock

Desert Control AS – Share capital increase registered

ISSUER DESERT CONTROL AS Sandnes, Norway, 6 August 2021: Reference is made to the stock exchange releaseby Desert Control ASA ("Desert Control" or the "Company") published on 5 July2021 regarding purchase of 63,000 shares by the Company's Chief TechnologyOfficer.The purchase of shares was carried out as part of the Company's employeeincentive program and was facilitated by the board of directors of the Company'sresolution on 5 July 2021 to increase the share capital, pursuant to theauthorisation granted by the Company's extraordinary general meeting on 6 April2021. The

BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

· Anti-TNFR2 antibody targets Treg mediated immunosuppression · Agreement supports the strong rationale for combining anti-TNFR2 and pembrolizumab in the ongoing Phase 1/2a trial · BI-1808 is one of three BioInvent drug candidates in clinical development Lund, Sweden – August 6, 2021 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that it has entered into a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent’s BI-1808, one of its

SAS Traffic figures - July 2021

Increased traveling during the summer resulted in over a million passengers in July.July was a month with increased numbers of travelers. More than a million passengers chose to fly with SAS, which is an increase of almost 70% compared with June. Capacity was raised during the month with increased frequency and destinations. The load factor ended at 60%, which is the highest number since February 2020. “We see the numbers improving gradually which is pleasing. However, we do naturally remain cautious as there are still a high number of uncertainties ahead of us. Remaining travel

David Phillips appointed Head of UK and Investor Relations of Aker Carbon Capture

David Phillips has been appointed Head of UK and Investor relations for Aker Carbon Capture effective August 1, 2021. He will also support Aker Horizons on investor relations.Phillips joins the company from HSBC’s Global Banking & Markets business, where he worked in London as Head of Equity Research for Europe, and before this in New York as Global Head of Resources & Energy Research. Phillips’ previous experience also includes roles at Aker Solutions, where he was responsible for Industry & Investor Relations.  “We are excited to welcome David Phillips back to the Aker family, in

SynAct Pharma strengthens its organization with two key recruitments

SynAct Pharma AB (“SynAct”) today announced the appointments of Patrik Renblad as Vice President Finance and Lise Agersted as Director of Operational R&D. Mr. Renblad will be responsible for the finance function reporting to the CFO. Mrs. Agersted will report to the CSO. Both starts immediately.Mr. Renblad joins SynAct after a decade in various financial roles at LEO Pharma A/S, where he was most recently Finance Director, R&D, leading the R&D Business Finance Organization and was a member of the LEO Pharma Finance and R&D Leadership teams. Prior to LEO Pharma, Mr. Renblad worked nine years

Bulletin from Extraordinary General Meeting in CELLINK AB (publ)

At the extraordinary general meeting in CELLINK AB (publ), held on August 6, 2021, the following resolutions were passed. The extraordinary general meeting resolved, in accordance with the proposal by the board of directors, to change the company name from CELLINK AB (publ) to BICO AB (publ) provided registration of the Swedish Companies Registration Office and to change the company’s objects in accordance with the following; The company shall acquire, own and manage real-, movable- and intellectual property, and mainly through subsidiaries conduct development, manufacturing and sale of

Contract extension for CSV Normand Pacific

Solstad Offshore ASA is pleased to announce that Prysmian Powerlink Srl (“Prysmian”) has exercised their option to extend the firm contract for CSV Normand Pacific with one year. The firm period will expire on December 31[st], 2022. In addition, Prysmian has the option to extend the contract with 2 years beyond the firm period. Normand Pacific has been on charter with Prysmian since August 2016. Skudeneshavn, August 6[th], 2021 ContactsLars Peder Solstad CEO, at +47 91 31 85 85Kjetil Ramstad CFO, at +47 90 75 94 89 Solstad Offshore ASAwww.solstad.com

Contract award in Brazil

Solstad Offshore ASA is pleased to announce a new contract for the CSV Normand Flower with PETROBRAS. The contract is for 3 years firm with 475 days options thereafter. Normand Flower will sail under REB Flag, supporting exploration and production activities in Brazilian continental shelf. Commencement of the contract will take place within April 2022. Skudeneshavn, August 5[th], 2021 Contacts Lars Peder Solstad CEO, at +47 91 31 85 85Kjetil Ramstad CFO, at +47 90 75 94 89 Solstad Offshore ASAwww.solstad.com

EAB Group Plc’s Board of Directors has decided on distribution of dividend

EAB Group Plc, Other information disclosed according to the rules of the Exchange, Stock Exchange Release, 6 August 2021, 9:10 a.m. (EET) EAB Group Plc’s Board of Directors has decided on distribution of dividend The Board of Directors of EAB Group Plc has decided to distribute a dividend of EUR 0.05 per share to shareholders in accordance with the mandate received from the Annual General Meeting (“AGM”) in 2021. The dividend of EUR 0.05 per share will be paid to shareholders who on the record date for the dividend payment on 31 August 2021 are recorded in EAB Group’s shareholders’

BERGENBIO ANNOUNCES CHANGES TO SENIOR MANAGEMENT

Bergen, Norway, 6 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces changes to its clinical development team structure in preparation for late-stage clinical trials of lead candidate bemcentinib and increased activity in medical and scientific regulatory affairs. Prof. Hani Gabra has transitioned from Chief Medical Officer to a part-time position as Director of Clinical Development, to focus on the scientific elements of clinical trial design and the

Artificial Solutions: Invitation to presentation of Q2 report 2021

Artificial Solutions® (SSME:ASAI), the leading specialist in enterprise-strength conversational AI, will release the interim report for the second quarter of 2021 on Tuesday 10th August at 07:30am (CET)The full report and a brief presentation will be available on: https://www.investors.artificialsolutions.com/financial-reports.Conference Call – DetailsPer Ottosson, CEO and Fredrik Törgren, CFO will present the financial results at a telephone conference at 10:00 CET on the same day. To participate in the conference call, please use the dial-in details below. Callers are encouraged to

Interim Report January – June 2021

Highlights Financial · Streaming sales up 19% from Q2 2020 to 545 (459) MSEK, +22% with constant exchange rates · Subscriber base up 29% from Q2 2020 to 1,626,900 (1,257,000) on average · Net turnover increased to 641 (554) MSEK in Q2 2021 · Earnings per share, after taxes amounted to -2.04 (-0.91) SEK in Q2 2021, before and after dilution Other · Held the Annual General Meeting of Shareholders on May 4 · Signed agreement to acquire the Finnish publishing house Aula & Co AB · Entered into a partnership with Spotify making Storytel’s catalogue available on the

Irisity AB (publ) delivers a second quarter with strong growth

The CEO comments on the second quarter: Net sales during the period amounted to SEK 13.1 million (9.6) and capitalized work to SEK 2.8 million (1.0). EBITDA amounted to SEK -2.6 million (-0.1) and profit after tax to SEK -6.0 million (-3.5). The gross margin was 58.2 percent (67.6). Cash and cash equivalents at the end of the period SEK 47.5 M (30.6). We finished the second quarter strong with net sales increasing by 36 percent and monthly recurring revenue (MRR) by 58 percent on a quarterly basis. During the period gross margin and EBITDA were burdened by new recruitments and many

Mika Vehviläinen selected as President and CEO of the Future Company as from completion of the merger between Konecranes and Cargotec

KONECRANES PLC INSIDE INFORMATION August 6, 2021 at 9:00 EEST Mika Vehviläinen selected as President and CEO of the Future Company as from completion of the merger between Konecranes and Cargotec On 1 October 2020, Konecranes Plc (“Konecranes”) and Cargotec Corporation (“Cargotec”) announced that the boards of the companies had signed a combination agreement and plan to combine the two companies through a merger (the “Future Company”), subject to regulatory and other approvals (the “Transaction”). The Boards of Directors of Konecranes and Cargotec have agreed to select Mr. Mika

Invitation to a press conference: Kamux Corporation’s Half-Year Report for January—June 2021

Kamux Corporation     Investor News      August 6, 2021 at 9:00 (EEST) Invitation to a press conference: Kamux Corporation’s Half-Year Report for January—June 2021 Kamux Corporation will publish its Half-Year Report for January-June on August 13, 2021 at about 9:00 a.m. Kamux will hold a Half-Year Report press conference and webcast for media and analysts on Friday August 13, 2021 at Hotel Kämp, Symposion meeting room (address Pohjoisesplanadi 29, Helsinki) at 11:00 (EEST) in Finnish and then in English at around 12:00 (EEST). You can follow the live webcast in Finnish through a

EAB Group Plc’s half-year report for January–June 2021: The Group's operating income increased by 21% and the result for the period improved by EUR 1.6 million

EAB Group Plc, Stock Exchange Release, 6 August 2021, 9:00 a.m. (EET) EAB Group Plc’s half-year report for January–June 2021: The Group's operating income increased by 21% and the result for the period improved by EUR 1.6 million In January–June 2021, the EAB Group's (later EAB or the Group) operating income increased by 21% and the result improved by EUR 1.6 million from the comparison period (EUR 0.8 million result in H1/2021 and EUR 0.75 million loss in H1/2020) as a result of increased operating income and efficiency measures introduced in 2020. The Group's continuing operating

NURMINEN LOGISTICS PLC HALF-YEAR FINANCIAL REPORT 1 JANUARY–30 JUNE 2021

Nurminen Logistics Plc                                                   Half-year Financial Report August 6, 2021 at 9:00 a.m.   Growth at the beginning of the year was very strong. Net sales increased by 73 per cent to EUR 63.0 million and net operating profit improved to EUR 3.7 millionThis release is a summary of Nurminen Logistics' Half-year Financial Report January-June 2021. The full report is attached to this stock exchange release and is available on Nurminen Logistics' website at nurminenlogistics.com  KEY FIGURES 1.1.–30.6.2021 1.1.–30.6.2020

President and CEO Rob Smith to leave Konecranes

KONECRANES PLC STOCK EXCHANGE RELEASE August 6, 2021 at 8:58 EEST President and CEO Rob Smith to leave Konecranes Konecranes President and CEO Rob Smith has decided to leave the company. He will leave Konecranes on 31 December 2021. The company's CFO, Teo Ottola, who also serves as Deputy CEO, will be acting as the interim CEO from 1 January 2022 until the completion of the planned merger between Konecranes and Cargotec Corporation, which is currently expected by the end of H1/2022. “Rob has been a true leader for Konecranes since joining in February 2020, steering the company

There are no items matching the current filter
There are no more items matching the current filter
Back to top